Annis Gardner Whiting Capital Advisors, LLC Krystal Biotech, Inc. Transaction History
Annis Gardner Whiting Capital Advisors, LLC
- $355 Billion
- Q3 2024
A detailed history of Annis Gardner Whiting Capital Advisors, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Annis Gardner Whiting Capital Advisors, LLC holds 10 shares of KRYS stock, worth $1,904. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10Holding current value
$1,904% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding KRYS
# of Institutions
310Shares Held
24.4MCall Options Held
483KPut Options Held
364K-
Black Rock Inc. New York, NY3.95MShares$752 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$543 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$499 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$277 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$188 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.89B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...